Ramiro Ribeiro sold $727k of EYPT
Chief Medical Officer at EyePoint Pharmaceuticals, Inc.. 42,544 shares at an average of $17.10, traded Jan 5, 2026, filed Jan 7, 2026.
Score components
- +15RoleOfficer
- +21Trade size$727k at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -23.4%, 3m -18.4%, 6m -19.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002013623-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 5, 2026 | MOption exercise Common Stock10b5-1 | +29,250 | $8.26 | $242k | 42,544 | Jan 7, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -42,544 | $17.10 | $727k | 0 | Jan 7, 2026 |
| Jan 5, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -29,250 | $0.00 | $0 | 87,750 | Jan 7, 2026 |
Related signals
Other insiders at EyePoint Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | EYPTbuy EyePoint Pharmaceuticals, Inc. | Karen L. Zaderej director | $52k 10,600 shares | +28% | |
| 8Weak | EyePoint Pharmaceuticals, Inc. | Ramiro Ribeiro Chief Medical Officer | $73k 4,875 shares | -100% | |
| 6Weak | EyePoint Pharmaceuticals, Inc. | Ramiro Ribeiro Chief Medical Officer | $37k 2,437 shares | -100% | |
| 29Weak | EYPTbuy EyePoint Pharmaceuticals, Inc. | Jay S. Duker President and CEO | $20k 1,500 shares | +2% | |
| 6Weak | EyePoint Pharmaceuticals, Inc. | Ramiro Ribeiro Chief Medical Officer | $44k 2,438 shares | -100% | |
| 6Weak | EyePoint Pharmaceuticals, Inc. | Ramiro Ribeiro Chief Medical Officer | $37k 2,437 shares | -100% | |
| 40Moderate | EyePoint Pharmaceuticals, Inc. | Cormorant Asset Management, LP other | $942k 60,000 shares | -1% | |
| 14Weak | EyePoint Pharmaceuticals, Inc. | Nancy Lurker Executive Vice Chair | $140k 9,300 shares | -4% | |
| 3Weak | EyePoint Pharmaceuticals, Inc. | Nancy Lurker Executive Vice Chair | $10k 700 shares | -0% | |
| 20Weak | EyePoint Pharmaceuticals, Inc. | Ramiro Ribeiro Chief Medical Officer | $32k 2,722 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.